Cipherome Leadership Visits DHR Health to Discuss the Value of Genetic-Based Study in Patients Undergoing Percutaneous Coronary Intervention

Translate to Spanish or other 102 languages!

Mega Doctor News

- Advertisement -

Edinburg, TX – Patients undergoing Percutaneous Coronary Intervention (PCI) or stent placement, after a stroke or heart attack require treatment that would reduce the risk of ischemic events without increasing the risk of bleeding. In addition to Aspirin, Plavix (Clopidogrel) is the most commonly used drug for this purpose and has been shown to reduce the risk of acute cardiac events and mortality.  To be effective, Plavix has to be activated in the liver, but some people have defective process thus reducing its therapeutic value.

DHR Health and DHR Health Institute for Research & Development are working with Cipherome, Inc., to use their genetic technology to determine if a patient undergoing PCI for coronary events has an intact pathway to metabolize Plavix. Over 90 patients have already been recruited in this study and a total of 350 patients will be recruited in the next few months.   

As the first gene-based study to be piloted in the Rio Grande Valley, Dr. Jane Chiang, chief medical officer and Jose Estabil, chief business officer at Cipherome, Inc., visited with DHR Health and DHR Health Institute for Research and Development leadership to discuss the value of this personalized medicine study that began back in December of 2020.  Cipherome, Inc. preferred South Texas for this pilot project to better understand how the genetic differences in Hispanic/Latino patients relate to the effectiveness and safety of medications used to treat them. 

- Advertisement -

“The use of this technology will allow the physicians at DHR Health to predict how a patient undergoing PCI will respond to Plavix therapy based on that patient’s genetic makeup” said Dr. Sohail Rao, president and chief executive officer at DHR Health Institute for Research and Development.  “This study continues to build on the DHR Health vision to practice advanced medicine and to bring the most innovative clinical care to the community”.  

For more information on research studies, please contact Dr. Sohail Rao, president and chief executive officer at DHR Health Institute for Research and Development at (956) 362-2387 or visit www.dhrresearch.org. 

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Keep Thanksgiving Stress-Free with STHS Food Safety Tips

The holiday season is a time for gathering with loved ones, celebrating family traditions and enjoying home-cooked meals. 

Cybersecurity Alert as Hackers Exploit Computer and Smartphone Vulnerabilities

Federal cybersecurity authorities are urging computer and smartphone users to keep their devices updated following reports of actively exploited security vulnerabilities affecting Apple products and Google’s Chrome browse

DHR Health Recognizes November as “National Hospice and Palliative Care” Month

DHR Health is pleased to recognize November as “National Hospice and Palliative Care Month.”  As we highlight National Hospice and Palliative Care Month, let us remember that healthcare is not solely about treating diseases but also about care for people at end of life.

STHS Heart Earns Healthgrades Five-Star Rating for Pacemaker Procedures

Healthgrades, the leading online resource for information about physicians and hospitals, has named STHS Heart a Five-Star Recipient for Pacemaker Procedures in 2027 for the second consecutive year, recognizing the facility's superior clinical outcomes and commitment to patient care.
- Advertisement -